Oz Adler sold $40k of PLRZ
director at Polyrizon Ltd.. 3,292 shares at an average of $12.05, traded Mar 31, 2026, filed Apr 1, 2026.
Score components
- +15RoleDirector
- +6Trade size$40k at market
- +5Share of holdings soldSold 14% of holdings
- +15Cluster4 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +26.9%, 3m +0.6%, 6m -14.5%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-26-038525, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 31, 2026 | SOpen-market sale Ordinary Shares | -3,292 | $12.05 | $40k | 19,850 | Apr 1, 2026 |
Related signals
Other insiders at Polyrizon Ltd. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 35Weak | Polyrizon Ltd. | Liron Carmel director | $12k 942 shares | -23% | |
| 40Moderate | Polyrizon Ltd. | Tomer Izraeli Chief Executive Officer | $5,925 500 shares | -2% | |
| 30Weak | Polyrizon Ltd. | Liron Carmel director | $1,100 100 shares | -2% | |
| 51Moderate | Polyrizon Ltd. | Tomer Izraeli Chief Executive Officer | $43k 3,900 shares | -11% | |
| 40Moderate | Polyrizon Ltd. | Tidhar Turgeman Chief Technology Officer | $32k 2,917 shares | -14% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.